Summary
News announcement about GSK's negotiations with the Indian government for introducing its patented drug Relenza, which is used for the treatment of Influenza A H1N1.
Analysis
This is a snapshot of what is actually going on--on a global realm. More and more people/companies/countries are buying larger and larger quantities of vaccines for H1N1 influenza.
To be honest with you, I view the swine flu just like dying in an airplane crash.....it is LOW RISK, but HIGH ALARM.
In essence, it is more than 1000 times more likely to die in a car crash than a plane crash, but everyone is scared to death of dying in a plane crash. (and not a car collision).
Swine flu is the same way....there are thousands of other things we need to think about and worry ourselves with with are more likely and will kill us faster.
More power to people who want to "be prepared" by having vaccinations, but these are very low yield........you would have to vaccinate about 100,000 people to prevent just one death from swine flu. Maybe even more than 100k people.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
